https://www.stocktitan.net/news/VTGN/vistagen-reports-fiscal-year-2027-second-quarter-financial-results-6ss9y7tvi4ek.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/VTGN/vistagen-reports-fiscal-year-2027-second-quarter-financial-results-6ss9y7tvi4ek.html?utm_source=stocktitan-bluesky&utm_medium=social
On November 9, 2026, Vistagen Therapeutics, Inc. announced a regulatory update from its recent, productive Type C meeting with the U.S. Food and Drug Administration to discuss potential registrational paths forward for the development of its lead product candidate, fasedienol, in social a...
On November 9, 2026, Vistagen Therapeutics, Inc. announced a regulatory update from its recent, productive Type C meeting with the U.S. Food and Drug Administration to discuss potential registrational paths forward for the development of its lead product candidate, fasedienol, in social a...
https://www.stocktitan.net/news/VTGN/vistagen-provides-regulatory-update-following-productive-type-c-l0i84z9j4hwl.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/VTGN/vistagen-provides-regulatory-update-following-productive-type-c-l0i84z9j4hwl.html?utm_source=stocktitan-bluesky&utm_medium=social
Mon close $0.17: below SMA50, below SMA200, RSI deeply oversold.
Hub: www.merlintrader.com/vistagen-the...
Not investment advice.
Mon close $0.17: below SMA50, below SMA200, RSI deeply oversold.
Hub: www.merlintrader.com/vistagen-the...
Not investment advice.
No valid summary extracted.
No valid summary extracted.
New hub updated: www.merlintrader.com/vistagen-the...
New hub updated: www.merlintrader.com/vistagen-the...
New hub updated: www.merlintrader.com/vistagen-the...
New hub updated: www.merlintrader.com/vistagen-the...
Interactive chart at JC Just Charts: justcharts.merlintrader.com#VTGN
Not investment advice.
Interactive chart at JC Just Charts: justcharts.merlintrader.com#VTGN
Not investment advice.
https://www.merlintrader.com/vistagen-therapeutics-stock-hub/
https://www.merlintrader.com/vistagen-therapeutics-stock-hub/
https://www.stocktitan.net/news/VTGN/vistagen-selects-gatc-health-to-apply-predictive-ai-across-lead-ft4lsluy859r.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/VTGN/vistagen-selects-gatc-health-to-apply-predictive-ai-across-lead-ft4lsluy859r.html?utm_source=stocktitan-bluesky&utm_medium=social
Amendment and Restatement of Executive Severance Plan On October 7, 2026, the Board of Directors of Vistagen Therapeutics, Inc. approved an amendment and restatement of the Company’s Change in Control Executive Severance Plan, which was originally adopted effective August 11, 2026 and des...
Amendment and Restatement of Executive Severance Plan On October 7, 2026, the Board of Directors of Vistagen Therapeutics, Inc. approved an amendment and restatement of the Company’s Change in Control Executive Severance Plan, which was originally adopted effective August 11, 2026 and des...
Amendment and Restatement of Executive Severance Plan On October 7, 2026, the Board of Directors of Vistagen Therapeutics, Inc. approved an amendment and restatement of the Company’s Change in Control Executive Severance Plan, which was originally adopted effective August 11, 2026 and des...
Amendment and Restatement of Executive Severance Plan On October 7, 2026, the Board of Directors of Vistagen Therapeutics, Inc. approved an amendment and restatement of the Company’s Change in Control Executive Severance Plan, which was originally adopted effective August 11, 2026 and des...
Vistagen Therapeutics (#$VTGN): What Is Left of Fasedienol After PALISADE-4, and What Happens Before February 1, 2027?
What to watch: www.merlintrader.com/vistagen-the...
Vistagen Therapeutics (#$VTGN): What Is Left of Fasedienol After PALISADE-4, and What Happens Before February 1, 2027?
What to watch: www.merlintrader.com/vistagen-the...
Vistagen Therapeutics, Inc. filed an 8-K on September 25, 2026, disclosing that it began utilizing a new corporate presentation (Exhibit 99.1) under Regulation FD.
🧵 continued ↓
Vistagen Therapeutics, Inc. filed an 8-K on September 25, 2026, disclosing that it began utilizing a new corporate presentation (Exhibit 99.1) under Regulation FD.
🧵 continued ↓
On September 25, 2026, Vistagen Therapeutics, Inc. began utilizing a new corporate presentation, a copy of which is attached to this Current Report on Form 8-K as Exhibit 99.1. The information under this Item 7.01 and Exhibit 99.1 attached hereto are intended to be furnished and shall not...
On September 25, 2026, Vistagen Therapeutics, Inc. began utilizing a new corporate presentation, a copy of which is attached to this Current Report on Form 8-K as Exhibit 99.1. The information under this Item 7.01 and Exhibit 99.1 attached hereto are intended to be furnished and shall not...
https://8KSpy.com
$BENF $VTGN $KXIN $HOWL $TURB
[img]DDAmanda.com/Charts/...]
https://8KSpy.com
$BENF $VTGN $KXIN $HOWL $TURB
[img]DDAmanda.com/Charts/...]
On September 24, 2026, Vistagen Therapeutics, Inc. issued a press release summarizing positive exploratory efficacy data presented by the Company at Psych Congress 2026. The poster highlights a potential efficacy signal for fasedienol nasal spray, the Company's rapid-onset Phase 3 product...
On September 24, 2026, Vistagen Therapeutics, Inc. issued a press release summarizing positive exploratory efficacy data presented by the Company at Psych Congress 2026. The poster highlights a potential efficacy signal for fasedienol nasal spray, the Company's rapid-onset Phase 3 product...
https://www.stocktitan.net/news/VTGN/vistagen-reports-positive-findings-supporting-fasedienol-s-potential-5fwo813pq73y.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/VTGN/vistagen-reports-positive-findings-supporting-fasedienol-s-potential-5fwo813pq73y.html?utm_source=stocktitan-bluesky&utm_medium=social
prismmarketview.com/vistagen-hig...
prismmarketview.com/vistagen-hig...
On the upside: Year-over-year quarterly revenue growth of 504.9%.
https://market-scanner.net/tickers/VTGN.US
#ai #trading
On the upside: Year-over-year quarterly revenue growth of 504.9%.
https://market-scanner.net/tickers/VTGN.US
#ai #trading